Jordan L Schultz1, John A Kamholz2, David J Moser2, Shawna M E Feely2, Jane S Paulsen2, Peg C Nopoulos2. 1. From the Departments of Pharmaceutical Care (J.L.S.), Neurology (J.L.S., J.A.K., S.M.E.F., J.S.P., P.C.N.), Psychiatry (J.A.K., D.J.M., J.S.P., P.C.N.), and Pediatrics (P.C.N.), The University of Iowa Hospitals and Clinics, Iowa City. Jordan-schultz@uiowa.edu. 2. From the Departments of Pharmaceutical Care (J.L.S.), Neurology (J.L.S., J.A.K., S.M.E.F., J.S.P., P.C.N.), Psychiatry (J.A.K., D.J.M., J.S.P., P.C.N.), and Pediatrics (P.C.N.), The University of Iowa Hospitals and Clinics, Iowa City.
Abstract
OBJECTIVE: To investigate the relationship between substances of abuse and age at motor onset (AMO) in patients with Huntington disease (HD) in a large and diverse patient population. METHODS: This was a retrospective, observational study of the Enroll-HD database. Participants were determined to belong to 1 of 3 substance abuse groups: (1) tobacco abusers, (2) alcohol abusers, and (3) drug abusers. A group of participants who had never abused substances served as a control group. The average AMO of patients in the substance abuse groups was compared to the control group. The number of CAG repeats was used as a covariate in all analyses. RESULTS: The average difference in AMOs of participants in the tobacco (n = 566), alcohol (n = 374), and drug abuse groups (n = 217) compared to the control group (n = 692) were 2.3 (F1, 1,258 = 33.8, p < 0.0001), 1.0 (F1, 1,066 = 4.2, p = 0.04), and 3.3 (F1, 909 = 29.7, p < 0.0001) years earlier, respectively. In all substance abuse groups, the AMO was lowered to a greater degree in female participants than it was in male participants. CONCLUSIONS: Substances of abuse have a strong effect on the AMO in patients with HD. These effects seem to be amplified in women with HD compared to men. These results may provide a safe intervention capable of adding disease-free years to patients with HD.
OBJECTIVE: To investigate the relationship between substances of abuse and age at motor onset (AMO) in patients with Huntington disease (HD) in a large and diverse patient population. METHODS: This was a retrospective, observational study of the Enroll-HD database. Participants were determined to belong to 1 of 3 substance abuse groups: (1) tobacco abusers, (2) alcohol abusers, and (3) drug abusers. A group of participants who had never abused substances served as a control group. The average AMO of patients in the substance abuse groups was compared to the control group. The number of CAG repeats was used as a covariate in all analyses. RESULTS: The average difference in AMOs of participants in the tobacco (n = 566), alcohol (n = 374), and drug abuse groups (n = 217) compared to the control group (n = 692) were 2.3 (F1, 1,258 = 33.8, p < 0.0001), 1.0 (F1, 1,066 = 4.2, p = 0.04), and 3.3 (F1, 909 = 29.7, p < 0.0001) years earlier, respectively. In all substance abuse groups, the AMO was lowered to a greater degree in female participants than it was in male participants. CONCLUSIONS: Substances of abuse have a strong effect on the AMO in patients with HD. These effects seem to be amplified in women with HD compared to men. These results may provide a safe intervention capable of adding disease-free years to patients with HD.
Authors: Jason C Ehret; Patricia S Day; Ryan Wiegand; Joanne Wojcieszek; R Andrew Chambers Journal: Drug Alcohol Depend Date: 2006-08-22 Impact factor: 4.492
Authors: O J Buruma; W Van der Kamp; E C Barendswaard; R A Roos; D Kromhout; E A Van der Velde Journal: J Neurol Sci Date: 1987-09 Impact factor: 3.181
Authors: Nancy S Wexler; Judith Lorimer; Julie Porter; Fidela Gomez; Carol Moskowitz; Edith Shackell; Karen Marder; Graciela Penchaszadeh; Simone A Roberts; Javier Gayán; Denise Brocklebank; Stacey S Cherny; Lon R Cardon; Jacqueline Gray; Stephen R Dlouhy; Sandra Wiktorski; Marion E Hodes; P Michael Conneally; Jack B Penney; James Gusella; Jang-Ho Cha; Michael Irizarry; Diana Rosas; Steven Hersch; Zane Hollingsworth; Marcy MacDonald; Anne B Young; J Michael Andresen; David E Housman; Margot Mieja De Young; Ernesto Bonilla; Theresa Stillings; Americo Negrette; S Robert Snodgrass; Maria Dolores Martinez-Jaurrieta; Maria A Ramos-Arroyo; Jacqueline Bickham; Juan Sanchez Ramos; Frederick Marshall; Ira Shoulson; Gustavo J Rey; Andrew Feigin; Norman Arnheim; Amarilis Acevedo-Cruz; Leticia Acosta; Jose Alvir; Kenneth Fischbeck; Leslie M Thompson; Angela Young; Leon Dure; Christopher J O'Brien; Jane Paulsen; Adam Brickman; Denise Krch; Shelley Peery; Penelope Hogarth; Donald S Higgins; Bernhard Landwehrmeyer Journal: Proc Natl Acad Sci U S A Date: 2004-03-01 Impact factor: 11.205
Authors: Lauren Jackson; Elizabeth A Coon; J Eric Ahlskog; James H Bower; Paola Sandroni; Eduardo E Benarroch; Jay N Mandrekar; Phillip A Low; Wolfgang Singer Journal: Parkinsonism Relat Disord Date: 2019-07-17 Impact factor: 4.891
Authors: Swati Sathe; Jen Ware; Jamie Levey; Eileen Neacy; Robi Blumenstein; Simon Noble; Alzbeta Mühlbäck; Anne Rosser; G Bernhard Landwehrmeyer; Cristina Sampaio Journal: Front Neurol Date: 2021-08-18 Impact factor: 4.086
Authors: Katherine E Odegaard; Gabriel Gallegos; Sneh Koul; Victoria L Schaal; Neetha N Vellichirammal; Chittibabu Guda; Andrea P Dutoit; Steven J Lisco; Sowmya V Yelamanchili; Gurudutt Pendyala Journal: Cells Date: 2022-05-25 Impact factor: 7.666
Authors: Naghmeh Ghazaleh; Richard Houghton; Giuseppe Palermo; Scott A Schobel; Peter A Wijeratne; Jeffrey D Long Journal: Front Neurol Date: 2021-05-20 Impact factor: 4.003
Authors: Alexander L Symonds; Antonella Macerollo; Kevin Foy; Sundus H Alusi; Rhys Davies Journal: Int J Environ Res Public Health Date: 2021-05-12 Impact factor: 3.390
Authors: Travis Cruickshank; Danielle Bartlett; Andrew Govus; Anthony Hannan; Wei-Peng Teo; Sarah Mason; Johnny Lo; Mel Ziman Journal: Brain Behav Date: 2020-03-17 Impact factor: 2.708